Navigation Links
Outlook improves for patients with non-Hodgkin lymphoma over past decade

Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Non-Hodgkin lymphoma includes several cancers of the immune system that occur in approximately 20.4 of every 100,000 individuals, according to background information in the article. Treatment for the condition has evolved rapidly in recent years.

Dianne Pulte, M.D., of the German Cancer Research Center, Heidelberg, and colleagues analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program of the U.S. National Cancer Institute. Survival rates were calculated based on two-year time periods between 1990 and 2004 within which patients were diagnosed with non-Hodgkin lymphoma, as well as by age group (15 to 44, 45 to 54, 55 to 64, 65 to 74 and 75 years or older), sex, race, tumor location (i.e. whether the disease was nodal [in the lymph nodes] or extranodal [in a site other than the lymph nodes]) and histologic subtype (to classify tumors as high-grade or low-grade).

Overall, five-year relative survival increased from 50.4 percent to 66.8 percent, and 10-year relative survival increased from 39.4 percent to 56.3 percent between 1990 to 1992 and 2002 to 2004, the authors write. Improvements were most pronounced in patients younger than 45 years (plus 26.8 and plus 27.1 percentage points for five- and 10-year survival, respectively), but improvements were seen in all age groups, in both sexes, in both nodal and extranodal disease and in both low-grade and high-grade disease. Improvements in prognosis were less in black patients than in white patients, especially in younger black patients.

Two factors may explain these improvements, the authors note. One is advances in therapy that have occurred between 1990 and 2004, particularly the introduction of antibody therapy for non-Hodgkin lymphoma, they write. Treatment with antibody therapy and chemotherapy has extended life expectancy in many cases, but whether and how often this extension represents a true cure is still unknown. In addition, improvements in the treatment of HIV have reduced the occurrence of HIV-related non-Hodgkin lymphomas and also made them easier to treat.

Our estimates of long-term survival in patients with non-Hodgkin lymphoma obtained by the period analysis method for the 2002 to 2004 period are much higher than previously available survival estimates, which mostly pertain to patients diagnosed in the 1990s, the authors conclude. Timely disclosure of the improvements in survival achieved in patients, clinicians, researchers and the public is essential.


Contact: Hermann Brenner
JAMA and Archives Journals

Related medicine news :

1. Gentiva(R) Health Services Announces Fourth Quarter and Fiscal 2007 Results, and Raises 2008 Outlook
2. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
3. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
4. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
5. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
6. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
7. Medco CEO Reiterates Guidance, Positive Outlook for 2008
8. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
9. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
10. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
11. Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... The North American Meat Institute today unveiled ... poultry play in a healthy, balanced diet. , includes a section about ... their “meat IQ,” a section offering straight talk on controversies, information on buying ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... oncology and hematology continuing medical education (CME), today announced that the first annual ... Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers are ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... professionals who believe that with innovative technologies and under the right circumstances, these ... get the benefit of a dual-approach to his or her therapeutic sessions, as ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ...
(Date:12/1/2015)... New York , December 1, 2015 ... Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives, Male ... Implants, Contraceptive Vaginal Rings, Contraceptive Diaphragms, Contraceptive ... Industry Analysis, Size, Share, Growth, Trends and ... released by Transparency Market Research (TMR).The report ...
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015   ... oncology drug development company, announces it has filed an ... and Drug Administration (FDA) for the Company,s lead fully ... Subject to FDA acceptance, MabVax plans to initiate the ... --> --> The planned ...
Breaking Medicine Technology: